Quad‐class exposed/refractory myeloma is associated with short survival - Nantes Université
Article Dans Une Revue British Journal of Haematology Année : 2023

Quad‐class exposed/refractory myeloma is associated with short survival

Résumé

Summary Very scarce data exist about outcomes of relapsed multiple myeloma patients who have failed proteasome inhibitor, immunomodulatory drug, anti‐CD38 monoclonal antibody and therapies targeting B‐cell maturation antigen (BCMA) (Quad‐class exposed [QCE]). In this retrospective single‐centre study, we determined progression‐free survival (PFS) and overall survival (OS) from anti‐BCMA failure in 45 QCE patients. Seven (16%) patients received antibody‐drug conjugate, 20 (44%) bispecific antibodies and 18 (40%) CAR‐T cell. Thirty patients (67%) received ≥1 subsequent line of treatment. PFS was 4.4 months (95% CI = 2.4–12.5) and OS 6.3 months (95% CI = 3.9–14.4). Having an adverse prognosis, QCE myeloma patients remain an unmet medical need.
Fichier non déposé

Dates et versions

hal-04753530 , version 1 (25-10-2024)

Identifiants

Citer

Bénédicte Piron, Domitille Costes-Tertrais, Thomas Gastinne, Aude Marie Fourmont, Viviane Dubruille, et al.. Quad‐class exposed/refractory myeloma is associated with short survival. British Journal of Haematology, 2023, 204 (1), pp.186-190. ⟨10.1111/bjh.19148⟩. ⟨hal-04753530⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More